Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(1): 31-34
DOI: 10.1055/s-0033-1358483
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Risk factors of Charcot Neuroarthropathy Development in Patients with Type 2 Diabetes

P. Nehring
1   Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland
,
B. Mrozikiewicz-Rakowska
1   Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland
,
P. Maroszek
1   Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland
,
A. Sobczyk-Kopcioł
2   Department of General Biology and Parasitology, Medical University of Warsaw, Poland
,
M. Krzyżewska
1   Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland
,
R. Płoski
3   Department of Medical Genetic, Medical University of Warsaw, Poland
,
W. Karnafel
1   Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland
› Author Affiliations
Further Information

Publication History

received 22 May 2013
first decision 19 August 2013

accepted 02 October 2013

Publication Date:
07 November 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Aim:

Charcot neuroarthropathy is a very rare form of diabetic foot syndrome occurring among others in patients with diabetes mellitus. Charcot neuroarthropathy leads to bone tissue destruction and may result in foot amputation. The aim of the study was to identify risk factors of Charcot neuroarthropathy occurrence in patients with diabetic foot and type 2 diabetes.

Materials:

The study included 144 patients with type 2 diabetes; 33 with Charcot neuroarthropathy and 111 with diabetic foot of neuropathic origin without neuroarthropathy. The study was perform in Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland.

Results:

The regression analysis showed that Charcot neuroarthropathy occurrence risk factors were: male gender (OR=4.94, 95% CI:1.63–15.03, p=0.003), age (OR=0.92, 95% CI:0.87–0.96, p=0.0001), diabetic foot duration (OR=1.19, 95% CI:1.08–1.32, p=0.00002) and height (OR=1.078, 95% CI:1.019–1.140, p=0.007). A positive effect on Charcot neuroarthropathy presence was exerted by body weight (OR=1.027, 95% CI:1.003–1.051, p=0.03) and hips circumference (OR=1.034, 95% CI:0.997–1.072, p=0.04).

Conclusions:

The existence of the specific factors influencing Charcot neuroarthropathy development may result in earlier identification of patients at risk of its development. There is a necessity to take special care for patients prone to develop Charcot neuroarthropathy in order to prevent its occurrence and severe complications.

Key words

neuropathy - obesity - peripheral arterial disease
 

  • References

  • 1 Kamińska A, Bronisz A, Kamiński M et al. Cukrzycowa neuroartropatia Charcota. Diabetologia Doświadczalna i Kliniczna 2004; 3: 175-179
    PubMedGoogle Scholar
  • 2 Nagarkatti DG, Banta JV, Thomson JD. Charcot arthropathy in spina bifida. J Pediatr Orthop 2000; 20: 82-87
    PubMedGoogle Scholar
  • 3 McKay DJ, Sheehan P, DeLauro TM et al. Vincristine-induced neuroarthropathy (Charcot’s joint). J Am Podiatr Med Assoc 2000; 90: 478-480
    PubMedGoogle Scholar
  • 4 Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: the Charcot foot. In: Fryberg RG. eds. The High Risk Foot in Diabetes Mellitus. New York: Churchill Livingstone; 1991: 297-338
    Google Scholar
  • 5 Petrova NL, Foster AVM, Edmonds ME et al. Difference in presentation of Charcot osteoarthropathy in type 1 compared with type 2 diabetes. Diabetes Care 2004; 27: 5
    CrossrefPubMedGoogle Scholar
  • 6 Rajbhandari SM, Jenkins RC, Davies C et al. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002; 45: 1085-1096
    CrossrefPubMedGoogle Scholar
  • 7 Stuck RM, Sohn MW, Budiman-Mak E et al. Charcot Arthropathy Risk Elevation in the Obese Diabetic Population. The American Journal of Medicine 2008; 11: 121
    PubMedGoogle Scholar
  • 8 Jeffcoate W, Lima J, Nobrega L. The Charcot foot. Diabet Med 2000; 17: 253-258
    CrossrefPubMedGoogle Scholar
  • 9 Fabrin J, Larsen K, Holstein PE. Long-term follow up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000; 23: 796-800
    CrossrefPubMedGoogle Scholar
  • 10 Berg EE. Charcot arthropathy after acetabular fracture. J Bone Joint Surg Br 1997; 79: 742-745
    CrossrefPubMedGoogle Scholar
  • 11 Armstrong DG, Todd WF, Lavery LA et al. The natural history of acute Charcot’s arthropathy in a diabetic foot speciality clinic. Diabet Med 1997; 14: 357-363
    CrossrefPubMedGoogle Scholar
  • 12 Slowman-Kovacs SD, Braunstein EM, Brandt KD. Rapidly progressive Charcot arthropathy following minor joint trauma in patients with diabetic neuropathy. Arthritis Rheum 1990; 33: 412-417
    CrossrefPubMedGoogle Scholar
  • 13 Charcot JM. Sur quelques arthropathies qui paraissent dependre d’une lesion du cerveau ou de la mouelle epiniere. Arch Physiol Norm Patol 1868; 1: 161-178
    PubMedGoogle Scholar
  • 14 Jeffcoate W. Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 2008; 24: 62-65
    CrossrefPubMedGoogle Scholar
  • 15 Gouveri E, Papanas N et al. Charcot osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice. World J Diabetes 2011; 5: 59-65
    PubMedGoogle Scholar
  • 16 Sinha S, Munichoodappa C, Kozak GP. Neuroarthropathy (Charcot’s joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972; 51: 191-210
    CrossrefPubMedGoogle Scholar
  • 17 Saltzman CL, Hagy ML, Zimmerman B et al. How effective is intensive nonoperative initial treatment of patients with diabetes and Charcot arthropathy of the feet?. Clin Orthop Relat Res 2005; 435: 185-190
    PubMedGoogle Scholar
  • 18 Musa HG, Ahmed ME. Associated risk factors and management of chronic diabetic foot ulcers exceeding 6 months’ duration. Diabetic Foot & Ankle. 2012: 3
    PubMedGoogle Scholar
  • 19 Sohn MW, Todd AL, Rodney MS. Mortality Risk of Charcot Arthropathy Compared With That of Diabetic Foot Ulcer and Diabetes Alone. Diabetes Care 2009; 32: 816-821
    CrossrefPubMedGoogle Scholar
  • 20 Sohn MW, Stuck RM, Pinzur M et al. Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer. Diabetes Care 2010; 33: 98-100
    CrossrefPubMedGoogle Scholar
  • 21 Holzer SE, Camerota A, Martens L et. al. Costs and duration of care for Lower extremity ulcers in patients with diabetes. Clin Ther 1998; 20: 169-181
    CrossrefPubMedGoogle Scholar
  • 22 International Consensus on the Diabetic Foot and Practical Guidelines on the Management and Prevention of the Diabetic Foot 2007 . International Working Group on the Diabetic Foot/Consultative Section of the IDF. Amsterdam, the Netherlands, on DVD.
    Google Scholar
  • 23 Perkins BA, Olaleye D, Zinman B et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250-256
    CrossrefPubMedGoogle Scholar
  • 24 James WB. Classification of foot lesions in Diabetic patients. Levin and O’Neals. The Diabetic Foot 2008; 9: 221-226
    PubMedGoogle Scholar
  • 25 Eichenholtz SN. Charcot joints. Springfield (IL): Charles C. Thomas; 1996
    Google Scholar
  • 26 Leung HB, Ho YC, Wong WC. Charcot foot in a Hong Kong Chinese diabetic population. Hong Kong Med J 2009; 15: 191-195
    PubMedGoogle Scholar